Development and Finance Committee of Faisalabad Development Authority (FDA) unanimously approved the proposed annual budget for the Fiscal Year (FY) 2026-27 and the revised budget for the Fiscal Year 2025-26.
FDA budget approved for FY 2026-27
FAISALABAD, Jul 20 (APP): Development and Finance Committee of Faisalabad Development Authority (FDA) unanimously approved the proposed annual budget for the Fiscal Year (FY) 2026-27 and the revised budget for the Fiscal Year 2025-26.
This approval was granted during a meeting held with Director General FDA Muhammad Asif Choudhary in the chair at FDA Complex.
During meeting, Additional Director General FDA, Qaiser Abbas Rand, delivered a comprehensive briefing on the proposed budget for FY 2026-27, covering projected revenue, development and non-development expenditures, revenue generation strategies, fiscal discipline, and the Authority’s development targets for the coming year.
The meeting was attended by representatives of the Punjab Planning and Development Board, Secretary Housing, Urban Development and Public Health Engineering Department, and the Punjab Finance Department. Additional Deputy Commissioner (Finance & Planning) Mudassar Mumtaz, representing the Deputy Commissioner Faisalabad; Deputy Managing Director WASA, Shoaib Rashid, representing the Managing Director WASA, Chief Engineer FDA, Mehr Ayub; Directors Junaid Hassan Manj, Qaiser Javed, and Afnan Saeed Sandhu; Deputy Directors Finance Adnan Shehzad and Afzal Ansari, along with other concerned officers were also present in the meeting.
The Committee conducted a detailed review of the proposed development and non-development budget estimates for FY 2026-27, strategies for enhancing revenue generation, projected income, new development initiatives, improvements in urban infrastructure, enhancement of public service delivery, institutional reforms, departmental expenditures and the allocation of financial resources.
A comparative analysis of the revenue and expenditure position, budget targets and financial management for FY 2025-26 was also presented.
Committee members sought clarification on several points before unanimously endorsing the proposed budget.
Addressing the meeting, Director General FDA Muhammad Asif Choudhary thanked the representatives of the participating departments for their valuable contributions.
He stated that the FY 2026-27 budget had been prepared on the basis of a balanced, realistic, and revenue-oriented strategy.
He emphasized that reducing unnecessary expenditures, identifying new revenue streams, ensuring the efficient utilization of resources and maintaining financial discipline were among the budget’s key priorities.
